Nucleoside Analog Antifungal Drug Class List

Drugs in Drug Class: Nucleoside Analog Antifungal

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	ANCOBON	flucytosine	CAPSULE;ORAL	017001-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Bausch	ANCOBON	flucytosine	CAPSULE;ORAL	017001-002	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Novel Labs Inc	FLUCYTOSINE	flucytosine	CAPSULE;ORAL	204652-002	Jul 7, 2017	AB	RX	No	No
Strides Pharma	FLUCYTOSINE	flucytosine	CAPSULE;ORAL	212632-001	Apr 17, 2020	AB	RX	No	No

Nucleoside Analog Antifungal Market Analysis and Financial Projection

The nucleoside analogue antifungal market is characterized by steady growth driven by increasing fungal infection burdens and advancements in drug development, though it faces challenges such as patent expirations and generic competition. Here's a detailed analysis:

Market Dynamics

• Growth Drivers:

  • The global antifungal drugs market was valued at $10.24 billion in 2019, projected to reach $13.17 billion by 2027 (CAGR: 3.3%)[3], with nucleoside analogues like flucytosine playing a critical role in treating cryptococcosis and systemic candidiasis.
  • Rising immunocompromised populations (e.g., HIV/AIDS, cancer patients) amplify demand. Over 39 million people live with HIV globally (2022)[4], and invasive fungal infections cause ~1.5 million annual deaths[12].
  • Flucytosine, a nucleoside analogue, dominates the cryptococcosis therapeutics market ($2.2 billion in 2023)[15], often combined with amphotericin B for cryptococcal meningitis[13][16].

• Regional Trends:

  • North America leads with ~44% market share due to high healthcare spending and R&D[3][8].
  • Asia-Pacific grows fastest (CAGR: 5.2%)[15], driven by improving healthcare access and high infectious disease burdens[1].

• Challenges:

  • Drug resistance: Resistance to azoles and echinocandins pressures developers to innovate[6].
  • Toxicity and shortages: Flucytosine faces supply constraints in Europe despite WHO essential medicine status[13].

---

Patent Landscape

• Key Patents and Innovations:

  • Flucytosine remains off-patent, with generics from Aurobindo, Hikma, and Strides Pharma[16]. Only 35% of cryptococcosis-related patents show experimental efficacy[2][11].
  • MAT2203 (Matinas BioPharma): A 2021 U.S. patent protects its use with flucytosine for CNS cryptococcosis, extending protection to 2037[14].
  • Nucleoside antibiotic pipelines: Focus on repurposing analogues for bacterial/fungal infections (e.g., halogenated or azole-modified compounds)[7][10].

• R&D Trends:

  • Low investment: Only 295 patent families (1995–2015) target cryptococcosis, primarily from academia[11].
  • Combination therapies: New formulations (e.g., nebulized azoles) aim to overcome resistance[6].

---

Competitive Landscape

• Major Players: Gilead Sciences, Pfizer, Novartis, and Bayer lead the antifungal market[1][4]. Flucytosine is produced by generics, while novel nucleoside analogues face competition from:
  • New MOA antifungals: Fosmanogepix (Pfizer), ibrexafungerp (Scynexis), and olorofim (F2G Ltd.)[6].
  • Nanotechnology: Nanoparticle delivery systems (e.g., Pulmocide’s opelconazole)[6].

Drug Class	Market Share (2023)	Key Challenges
Nucleoside Analogues	$2.2B (flucytosine)[15]	Generic competition, resistance
Azoles	Dominant	Resistance, toxicity
Echinocandins	Growing	High cost, limited spectrum

---

Future Outlook

• Market Growth: The invasive fungal infections market will reach $9.6 billion by 2029 (CAGR: 4.8%)[4], with nucleoside analogues maintaining niche roles in combination therapies.
• Strategic Shifts:
  • Drug repurposing: Leveraging nucleoside analogues from antiviral/cancer pipelines for antifungal use[10].
  • Targeted delivery: Oral/intravenous LNC formulations (e.g., MAT2203) to improve efficacy[14].
  • Global health initiatives: Expanding access in low-income regions for cryptococcosis treatments[12][13].

In summary, while nucleoside analogues like flucytosine remain vital, innovation focuses on overcoming resistance through combination therapies and novel delivery systems. Limited patent activity underscores the need for increased R&D investment to address unmet needs in fungal infection treatment.

References

1. https://www.datamintelligence.com/research-report/nucleoside-analogues-market
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6358010/
3. https://www.fortunebusinessinsights.com/industry-reports/antifungal-drugs-market-101188
4. https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report
5. https://www.alliedmarketresearch.com/antifungal-drugs-market
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC8962932/
7. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.00952/full
8. https://www.grandviewresearch.com/industry-analysis/antifungal-drugs-market
9. https://patents.google.com/patent/WO2018049535A1/en
10. https://pmc.ncbi.nlm.nih.gov/articles/PMC6540614/
11. https://www.scielo.br/j/mioc/a/yV6twWPxYvpC6XcVdt4C8Sj/?lang=en
12. https://www.verifiedmarketreports.com/product/flucytosine-tablets-market/
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC10245318/
14. https://www.globenewswire.com/news-release/2021/08/16/2280948/0/en/Matinas-BioPharma-Announces-Issuance-of-U-S-Patent-Protecting-MAT2203-to-Treat-or-Prevent-Cryptococcus-Infections.html
15. https://www.gminsights.com/industry-analysis/cryptococcosis-therapeutics-market
16. https://www.drugpatentwatch.com/p/generic-api/FLUCYTOSINE